Fig. 3

Change in (A) monthly and (B) weekly average headache days of at least moderate severity in CM patients. Change in monthly average number of headache days of at least moderate severity represents mean change from baseline during the 4-week period after the first dose (ANCOVA analysis) while change in the weekly average number of headache days of at least moderate severity represents mean change per week during the 4-week period from the first dose (MMRM analysis). An asterisk denotes P < 0.05 and a dagger P < 0.0001 for the comparison with placebo. Fremanezumab is the sum of fremanezumab monthly and fremanezumab quarterly groups. Abbreviations: ANCOVA, analysis of covariance; LSM, least-squares mean; MMRM, mixed-effects model for repeated measures